Aprepitant

CLINICAL USE

Prevention of acute and delayed nausea
and vomiting associated with moderate and
highly emetogenic cancer chemotherapy

DOSE IN NORMAL RENAL FUNCTION

125 mg once daily on day 1 followed by 80 mg
once daily on days 2 and 3

PHARMACOKINETICS

Molecular weight &nbsp &nbsp &nbsp &nbsp &nbsp &nbsp &nbsp &nbsp &nbsp &nbsp &nbsp &nbsp &nbsp :
534.4

%Protein binding &nbsp &nbsp &nbsp &nbsp &nbsp &nbsp &nbsp &nbsp &nbsp &nbsp &nbsp &nbsp &nbsp :
>95

%Excreted unchanged in urine &nbsp &nbsp :
0

Volume of distribution (L/kg) &nbsp &nbsp &nbsp :
66 litres

half-life – normal/ESRD (hrs)&nbsp &nbsp &nbsp :
9–13/Unchanged

DOSE IN RENAL IMPAIRMENT

GFR (mL/MIN)

20 to 50 &nbsp &nbsp : Dose as in normal renal function

10 to 20 &nbsp &nbsp : Dose as in normal renal function

<10 &nbsp &nbsp &nbsp &nbsp &nbsp :
Dose as in normal renal function

DOSE IN PATIENTS UNDERGOING RENAL REPLACEMENT THERAPIES

CAPD &nbsp &nbsp &nbsp &nbsp &nbsp &nbsp &nbsp &nbsp:
Not dialysed. Dose as in normal renal function

HD &nbsp &nbsp &nbsp &nbsp &nbsp &nbsp &nbsp &nbsp &nbsp &nbsp :
Not dialysed. Dose as in normal renal function

HDF/high flux &nbsp :
Unlikely to be dialysed. Dose as in
normal renal function

CAV/VVHD &nbsp &nbsp &nbsp:
Not dialysed. Dose as in normal renal function

IMPORTANT DRUG INTERACTIONS

Potentially hazardous interactions with other drugs

Avoid concurrent administration with

pimozide or St John’s wort

Oestrogens and progestogens: may cause

contraceptive failure

ADMINISTRATION

Reconstition

–

Route

Oral

Rate of Administration

–

Comments

–

OTHER INFORMATION

Less than 0.2% of a dose is recovered in

dialysate after haemodialysis

Tags: post-by-auto-php